...
首页> 外文期刊>Heart failure reviews >Fibrosis and heart failure
【24h】

Fibrosis and heart failure

机译:纤维化和心力衰竭

获取原文
获取原文并翻译 | 示例
           

摘要

The extracellular matrix (ECM) is a living network of proteins that maintains the structural integrity of the myocardium and allows the transmission of electrical and mechanical forces between the myocytes for systole and diastole. During ventricular remodeling, as a result of iterations in the hemodynamic workload, collagen, the main component of the ECM, increases and occupies the areas between the myocytes and the vessels. The resultant fibrosis (reparative fibrosis) is initially a compensatory mechanism and may progress adversely influencing tissue stiffness and ventricular function. Replacement fibrosis appears at sites of previous cardiomyocyte necrosis to preserve the structural integrity of the myocardium, but with the subsequent formation of scar tissue and widespread distribution, it has adverse functional consequences. Continued accumulation of collagen impairs diastolic function and compromises systolic mechanics. Nevertheless, the development of fibrosis is a dynamic process wherein myofibroblasts, the principal cellular elements of fibrosis, are not only metabolically active and capable of the production and upregulation of cytokines but also have contractile properties. During the process of reverse remodeling with left ventricular assist device unloading, cellular, structural, and functional improvements are observed in terminal heart failure patients. With the advent of anti-fibrotic pharmacologic therapies, cellular therapy, and ventricular support devices, fibrosis has become an important therapeutic target in heart failure patients. Herein, we review the current concepts of fibrosis as a main component of ventricular remodeling in heart failure patients. Our aim is to integrate the histopathologic process of fibrosis with the neurohormonal, cytochemical, and molecular changes that lead to ventricular remodeling and its physiologic consequences in patients. The concept of fibrosis as living scar allows us to envision targeting this scar as a means of improving ventricular function in heart failure patients.
机译:细胞外基质(ECM)是蛋白质的生命网络,可以维持心肌的结构完整性,并允许在心肌细胞之间传递用于收缩和舒张的电动和机械力。在心室重塑期间,由于血液动力学负荷的反复变化,胶原蛋白(ECM的主要成分)增加并占据了肌细胞和血管之间的区域。最终的纤维化(修复性纤维化)最初是一种补偿机制,可能对组织的硬度和心室功能产生不利影响。置换性纤维化出现在先前的心肌细胞坏死的部位,以保留心肌的结构完整性,但随后形成的瘢痕组织和广泛分布,对功能产生不利影响。胶原蛋白的持续积累会损害舒张功能并损害收缩力学。然而,纤维化的发展是一个动态过程,其中成纤维细胞是纤维化的主要细胞成分,不仅具有代谢活性,并且能够产生和上调细胞因子,而且还具有收缩特性。在左心室辅助装置卸载的反向重塑过程中,晚期心力衰竭患者的细胞,结构和功能均得到改善。随着抗纤维化药物治疗,细胞疗法和心室支持设备的出现,纤维化已成为心力衰竭患者的重要治疗目标。本文中,我们回顾了纤维化作为心力衰竭患者心室重构的主要组成部分的当前概念。我们的目标是将纤维化的组织病理学过程与导致患者心室重塑及其生理后果的神经激素,细胞化学和分子变化相结合。纤维化作为活疤的概念使我们能够设想将这种疤痕作为改善心力衰竭患者心室功能的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号